Company Overview
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Why Investors Should Care
Revenue has grown at a 50920.4% CAGR over the past five years.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR 50920.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 50,920.41% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -35.37% |
| 6 Months: | -46.06% |
| 3 Months: | -7.83% |
| 1 Month: | -0.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.82 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 50920.4% over 5 years.
CONS
- Trading 58.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GRCE Grace Therapeutics, Inc. PHARMA | 2.12 | -1.81 | $44.60M | 0.00% | -17.17% | -36.19% | 50,920.41% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 81.00K | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | -8.01M | -6.25M | -6.15M | - | -4.12M | -8.03M | -1.96M | -3.15M | -3.57M | -4.47M | -4.73M | -5.11M | -4.25M | -4.45M | -2.09M | -3.04M | -4.96M | -4.83M | -3.70M | -3.09M | -2.53M | -2.45M |
| Net Income | -39.37M | -8.85M | -21.16M | -12.12M | -25.51M | -4.67M | -6.15M | -3.22M | -3.12M | 981.00K | -3.78M | -4.52M | -4.93M | -3.89M | -4.02M | -3.27M | -2.39M | -2.62M | -3.43M | -4.16M | -3.36M | -938.00K | -2.31M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.12 | -0.03 | -0.09 | -0.61 | -0.66 | -0.52 | -0.54 | -0.43 | -0.21 | -0.24 | -0.30 | -0.36 | -0.21 | -0.06 | -0.14 |
| R&D Expense | - | 6.19M | 3.95M | 3.91M | - | 1.76M | 1.29M | 678.00K | 469.00K | 585.00K | 2.18M | 2.59M | 3.29M | 2.45M | 1.09M | 460.00K | 1.44M | 2.71M | 2.98M | 2.19M | 955.00K | 568.00K | 462.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 196.00K | 100.00M | - | - | - | - |
| Operating Income | -34.41M | -24.44M | -16.42M | -15.59M | -52.16M | -12.85M | -16.68M | -11.08M |
| Net Income | -39.37M | -25.51M | -19.68M | -9.82M | -42.43M | -12.85M | -9.57M | -7.79M |
| Diluted EPS | - | - | - | -0.27 | -5.71 | -1.35 | -0.79 | -0.47 |
| R&D Expense | 29.37M | 15.97M | 4.17M | 5.56M | 9.97M | 4.68M | 9.51M | 2.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2018 | Dec 2018 | Mar 2019 | Dec 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 36.90M | - | 22.85M | 62.46M | 128.62M | 79.12M | 73.30M | 71.99M | 66.65M |
| Total Equity | 7.19M | - | 11.04M | - | 12.99M | 55.66M | 108.27M | 67.95M | 61.74M | 66.61M | 63.90M |
| Cash & Equivalents | - | 6.42M | 16.87M | 16.87M | 14.24M | 50.94M | 30.34M | 27.88M | 23.00M | 22.13M | 16.98M |
| Total Liabilities | - | - | 25.85M | - | 9.86M | 6.80M | 20.35M | 11.17M | 11.56M | 5.38M | 2.76M |
| Current Liabilities | - | - | 13.67M | - | 7.39M | 1.58M | 3.26M | 3.41M | 1.68M | 1.93M | 2.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.95M | -14.32M | -17.23M | -15.91M | -12.33M | -14.90M | -8.87M |
| Investing Cash Flow | 8.14M | -9.86M | -3.52M | 13.15M | 104.00K | 0 | 0 |
| Financing Cash Flow | 13.18M | 59.49M | 0 | 304.00K | 7.36M | 14.03M | 3.71M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -8,377.0% | -15.6% | - | - | - | - |
| Net Margin % | - | - | -10,039.8% | -9.8% | - | - | - | - |
| ROE % | -356.4% | -196.3% | -35.4% | -9.1% | -62.4% | -20.8% | -14.4% | -12.2% |
| ROCE % | -148.1% | -158.1% | -27.0% | -12.4% | -68.9% | -17.9% | -23.8% | -17.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cerity Partners LLC | 4.04% | 849.05K | $1.79M |
| 2 | Eversept Partners, LP | 3.67% | 772.90K | $1.63M |
| 3 | Bank of America Corporation | 2.35% | 494.70K | $1.04M |
| 4 | Vanguard Capital Management LLC | 1.96% | 411.71K | $868.72K |
| 5 | Citadel Advisors Llc | 1.66% | 349.74K | $737.95K |
| 6 | Maven Securities Limited | 0.95% | 200.00K | $422.00K |
| 7 | Birchview Capital, LP | 0.57% | 120.00K | $253.20K |
| 8 | Cantor Fitzgerald, L.P. | 0.48% | 100.00K | $211.00K |
| 9 | Two Sigma Investments, LP | 0.46% | 96.89K | $204.44K |
| 10 | Jane Street Group, LLC | 0.43% | 89.44K | $188.72K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GRCE
A drug company CEO's presentation goes online Sept. 11. He'll meet investors in New York. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQcTZjRnFrZy1vNWpiZHhCZWpqc05UTGtqWG5FSDYwSlBkb3hPcXdWVHVoeVVHdUtyNHYtVzlRT1FqVzRYNkd5Nk0xQ2NCYXUzeFpoZ1VpRHJLRUM5dWhEbW40SzAxUWw0dXVHa3pzZkV6VVJjWWdXWUQyVWZUWnFsUkp4aFBHbmkyY2ZJc3…
We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNdlhsWXI0UHlvdl9PUTRvRjlTNDJyS3o5WTlyWXRPWGZPRFFuc0lwbWhXak5laVZGaWg4ZzhZTkN4WW1Kc0podWx4eV9OaDBHdjdNMmtUT2kwU3ZmMFJGQk5NUk5CM24ybTh5eUZTQTlNRWtQQTNVMUN2RXMxVjFZdm9PN1FCR1RRTy1EMT…
Grace Therapeutics Reports $15.8 Million First-Quarter Net Loss - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPcVM3WFIwcng5Wk9ENks1NnNyWE8wLUpMQ2JpWl8tandmM05nRzRHdk1wRkNyUGo5M190c1lpNWd2bVRBZUdDUWh6ZnNxdnFJQVI3OGRlVHB0RFhTVzBCVFNrZG4xY0IwdU4yOWxxMUhsZ2JzX19lSnJiX0VPekJGRXZXVGR4R2Fwd1NCcz…
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNVDBvanlnSDJaeXItSjF0UlByQ0w1SUlLYVJRYVJlNnFZLWtpWVJ4YzE0RTFhbE42c0FnclZvLVdyY2lBVEJ5eFhXTlVnWk12RFhnYzNMRmZpYmtWMFd6c29OZFFsSXBPMGhfT2VVRW1aLTEwOXp4T0VVY3dQa1IzNjcxamVOU2pxc2J1QW…
GRCE - Grace Therapeutics Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE4yaHhwOGpoaVB4TTBSb1RiN2xCdXdOakhiR2JpRUhWRXpZTHRvYXdLQlBERTd6Ml9SUGExeEdVSWFxdVpXTkE?oc=5" target="_blank">GRCE - Grace Therapeutics Inc Stock Price and Quote</a> <font…
Opaleye Management buys $24,206 of Grace Therapeutics stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPZW4xdW15OEVHWFRTMHZFaGVhMlR1cmxJTFA5UmkwdTBKRlpPQm1HQllQNmVpemVWMEhnYlE2b0xLV0pNUlVJeWVzLVZ6ZENmaE5mMWFhMi01UWx6dzdCckdudGhXYTJTb1QyNWoyUWJYcWxTeG14VjZtMjdrempEc2IxVzRkY2xGNEhiNz…
GRCE — Frequently Asked Questions
What is the current share price of Grace Therapeutics, Inc. (GRCE)?
As of 2026-09-19 21:16 PDT, Grace Therapeutics, Inc. (GRCE) trades at $2.12 on NasdaqCM. Its 52-week range is $2.07 to $5.13.
What is the market capitalisation of GRCE?
Grace Therapeutics, Inc. (GRCE) has a market capitalisation of $44.60M on NasdaqCM.
What is the P/E ratio of GRCE?
GRCE trades at a trailing price-to-earnings (P/E) ratio of -1.81. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.71.
What is the return on equity (ROE) of GRCE?
GRCE has a return on equity (ROE) of -36.19%. Its return on capital employed (ROCE) is -17.17%.
Is GRCE a good stock to buy?
This page provides a data-driven analysis of Grace Therapeutics, Inc. (GRCE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.